BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou C, Wang Y, Ma L, Qian X, Yang C, Zeng M. Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis. Eur Radiol 2021. [PMID: 34279688 DOI: 10.1007/s00330-021-08188-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583-705. [PMID: 36263666 DOI: 10.3350/cmh.2022.0294] [Reference Citation Analysis]
2 Xiao Y, Zheng X, Zhou C, Huang P, Wu F, Yang C, Zeng M. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction. Eur Radiol. [DOI: 10.1007/s00330-022-09131-5] [Reference Citation Analysis]
3 Zhou C, Lu X, Wang Y, Qian X, Yang C, Zeng M. Histopathological components correlated with MRI features and prognosis in combined hepatocellular carcinoma-cholangiocarcinoma. Eur Radiol 2022. [PMID: 35976399 DOI: 10.1007/s00330-022-09065-y] [Reference Citation Analysis]
4 Xu J, Li S, Feng Y, Zhang J, Peng Y, Wang X, Wang H. The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery. CMAR 2022;Volume 14:1795-806. [DOI: 10.2147/cmar.s361462] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Sheng R, Sun W, Huang X, Jin K, Gao S, Zeng M, Wu D, Shi G. Apparent Diffusion Coefficient MRI Shows Association With Early Progression of Unresectable Intrahepatic Cholangiocarcinoma With Combined Targeted-Immunotherapy. J Magn Reson Imaging 2022. [PMID: 35488518 DOI: 10.1002/jmri.28214] [Reference Citation Analysis]
6 Wang Y, Zhu GQ, Zhou CW, Li N, Yang C, Zeng MS. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors. Eur Radiol 2022. [PMID: 35316365 DOI: 10.1007/s00330-022-08691-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sheng R, Huang X, Jin K, Gao S, Zeng M, Wu D, Shi G. Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma. Eur Radiol 2022. [PMID: 35298678 DOI: 10.1007/s00330-022-08679-6] [Reference Citation Analysis]
8 Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 2022;23. [DOI: 10.3348/kjr.2022.0822] [Reference Citation Analysis]